Brief: Guardant Health Launches Shield Multi-Cancer Detection (Mcd) Test In Multiple Markets In Asia With Manulife Partnership
16/03/2026 12:20
March 16 (Reuters) - Guardant Health Inc GH.O: GUARDANT HEALTH LAUNCHES SHIELD MULTI-CANCER DETECTION (MCD) TEST IN MULTIPLE MARKETS IN ASIA WITH MANULIFE PARTNERSHIP GUARDANT HEALTH INC - MANULIFE CUSTOMERS IN ASIA TO ACCESS SHIELD MCD TEST BEGINNING APRIL 2026 Source text: ID:nBw8JLs0ka Further company coverage: GH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Guardant Health
See all newsBrief: Guardant Health Announces Approval In Europe Of Guardant360® Cdx
Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
US Health Secretary Kennedy Jr. adds eight new members to key health committee (updated)
Brief: US FDA Grants Accelerated Approval To Etcamah For Advanced Breast Cancer With ESR1 Mutation
Brief: Guardant Health To Appeal Federal District Court Judgment